U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C2H5NO2.HI
Molecular Weight 278.0456
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLYCINE HYDRIODIDE

SMILES

I.NCC(O)=O.NCC(O)=O

InChI

InChIKey=VQKNNQCPNAEMNT-UHFFFAOYSA-N
InChI=1S/2C2H5NO2.HI/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);1H

HIDE SMILES / InChI

Molecular Formula HI
Molecular Weight 127.9124
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H5NO2
Molecular Weight 75.0666
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Glycine (Cly) is a natural amino acid neurotransmitter that acts as a co-agonist at Glutamate [NMDA] receptors in the brain and is an activator of glycine receptors, GLRA1-3, GLRB. The abnormal Gly levels have been implicated in neuropsychiatric disorders. Alterations in Gly levels are implicated in several diseases of the central nervous system. Glycine was studied in phase II of clinical trials in patients with schizophrenia. The results have shown that using of glycine was associated with reduced symptoms with promising effect sizes and a possibility of improvement in cognitive function. Besides, glycine was also studied in clinical trials phase II in children with cystic fibrosis. The clinical, spirometric and inflammatory status of subjects with cystic fibrosis improved after just 8 weeks of glycine intake, suggesting that this amino acid might constitute a novel therapeutic tool for these patients. In addition, Gly was proposed as a biomarker for brain tumor malignancy. Glycine is a component of a nutrients mixture for peripheral administration to well-nourished mildly catabolic adult patients who require only short-term parenteral nutrition.

CNS Activity

Curator's Comment: Known to be CNS non-penetrant in rabbit. Human data not available.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Preventing
FREAMINE III 8.5%

Approved Use

Aminosyn, Sulfite-Free, (a crystalline amino acid solution) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. SUPPLEMENTAL ELECTROLYTES, IN ACCORDANCE WITH THE PRESCRIPTION OF THE ATTENDING PHYSICIAN, MUST BE ADDED TO AMINOSYN SOLUTIONS WITHOUT ELECTROLYTES. Aminosyn can be administered peripherally with dilute (5 to 10%) dextrose solution and I.V. fat emulsion as a source of nutritional support. This form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. When administered with concentrated dextrose solutions with or without fat emulsions, Aminosyn is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where: (a) the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not be used; (b) gastrointestinal absorption of protein is impaired; (c) metabolic requirements for protein are substantially increased as with extensive burns and (d) morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown, thereby preserving tissue reserves, as in acute renal failure.

Launch Date

1971
PubMed

PubMed

TitleDatePubMed
Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of amino acid transport system A.
2000 Jul 31
Is the Ala138Gly alteration of MEFV gene important for amyloidosis?
2001
Mutant mice as a model for cerebellar ataxia.
2001 Apr
The effect of amino acid spacers on the antigenicity of dimeric peptide--inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans.
2001 Feb
The folate cycle and disease in humans.
2001 Feb
Distribution of transcripts for the brain-specific GDP/GTP exchange factor collybistin in the developing mouse brain.
2001 Feb
High-dose intravenous infusion of irrigating fluids containing glycine and mannitol in the pig.
2001 Feb
Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improvesoOutcome after brain trauma.
2001 Feb
Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids.
2001 Feb
Differential actions of PKA and PKC in the regulation of glutamate release by group III mGluRs in the entorhinal cortex.
2001 Feb
Glycine supply to human enterocytes mediated by high-affinity basolateral GLYT1.
2001 Feb
Amino acid interconversions in the fetal-placental unit: the animal model and human studies in vivo.
2001 Feb
Hamster sperm glycine receptor: evidence for its presence and involvement in the acrosome reaction.
2001 Feb
Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
2001 Feb 15
Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain.
2001 Feb 2
Critical role of the residue size at position 87 in H2O2- dependent substrate hydroxylation activity and H2O2 inactivation of cytochrome P450BM-3.
2001 Feb 9
Purification and characterization of two hemolysins from Stichodactyla helianthus.
2001 Feb-Mar
Ehlers-Danlos syndrome type IV with a unique point mutation in COL3A1 and familial phenotype of myocardial infarction without organic coronary stenosis.
2001 Jan
New polymorphisms in the interleukin-10 gene--relationships to myocardial infarction.
2001 Jan
An HphI polymorphism in the E-selectin gene is associated with premature coronary artery disease.
2001 Jan
A missense mutation encoding cys(67) --> gly in neurophysin ii is associated with early onset autosomal dominant neurohypophyseal diabetes insipidus.
2001 Jan
Determination of bile acids in biological fluids by liquid chromatography-electrospray tandem mass spectrometry.
2001 Jan
Postsynaptic currents in deep cerebellar nuclei.
2001 Jan
Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits.
2001 Jan
Regional distribution and pharmacological characteristics of [3H]N-acetyl-aspartyl-glutamate (NAAG) binding sites in rat brain.
2001 Jan
Regulation of a mammalian Shaker-related potassium channel, hKv1.5, by extracellular potassium and pH.
2001 Jan 12
Crystal structure of soybean proglycinin A1aB1b homotrimer.
2001 Jan 12
Intensity-dependent, rapid activation of presynaptic metabotropic glutamate receptors at a central synapse.
2001 Jan 15
Familial Tetralogy of Fallot caused by mutation in the jagged1 gene.
2001 Jan 15
Flavonoid 6-hydroxylase from soybean (Glycine max L.), a novel plant P-450 monooxygenase.
2001 Jan 19
Ultrastructural evidence for direct projections from the pontine micturition center to glycine-immunoreactive neurons in the sacral dorsal gray commissure in the cat.
2001 Jan 22
Acylation of lysine 983 is sufficient for toxin activity of Bordetella pertussis adenylate cyclase. Substitutions of alanine 140 modulate acylation site selectivity of the toxin acyltransferase CyaC.
2001 Jan 5
The function of Arg-94 in the oxidation and decarboxylation of glutaryl-CoA by human glutaryl-CoA dehydrogenase.
2001 Jan 5
Genetics, an alternative way to discover, characterize and understand ion channels.
2001 Jan-Feb
Pet111p, an inner membrane-bound translational activator that limits expression of the Saccharomyces cerevisiae mitochondrial gene COX2.
2001 Mar 2
Amino acid residue penultimate to the amino-terminal gly residue strongly affects two cotranslational protein modifications, N-myristoylation and N-acetylation.
2001 Mar 30
Patents

Sample Use Guides

Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
Route of Administration: Oral
The excess of glycine inhibits the growth of many bacteria, and it is used as a nonspecific antiseptic agent due to its low level of toxicity in animals. The MIC at which 90% of strains are inhibited for glycine was almost 2.5 mg/ml for 31 strains of H. pylori, including CLR-resistant strains.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:12:15 GMT 2023
Edited
by admin
on Fri Dec 15 15:12:15 GMT 2023
Record UNII
J56052844H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLYCINE HYDRIODIDE
Systematic Name English
DIGLYCOCOLL HYDRIODIDE
Common Name English
DIGLYCOCOLL HYDROIODIDE
Common Name English
GLYCINE, HYDRIODIDE (2:1)
Common Name English
Code System Code Type Description
CAS
7490-96-2
Created by admin on Fri Dec 15 15:12:15 GMT 2023 , Edited by admin on Fri Dec 15 15:12:15 GMT 2023
PRIMARY
FDA UNII
J56052844H
Created by admin on Fri Dec 15 15:12:15 GMT 2023 , Edited by admin on Fri Dec 15 15:12:15 GMT 2023
PRIMARY
PUBCHEM
62707348
Created by admin on Fri Dec 15 15:12:15 GMT 2023 , Edited by admin on Fri Dec 15 15:12:15 GMT 2023
PRIMARY
EPA CompTox
DTXSID20225879
Created by admin on Fri Dec 15 15:12:15 GMT 2023 , Edited by admin on Fri Dec 15 15:12:15 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE